Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Complement C1”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1977

Interactions between mycoplasma pneumoniae and the first components of complement.

Mycoplasma pneumoniae cells were rounded and killed by fresh guinea pig serum (GPS) which did not contain detectable amounts of antibody. The first component of complement (C1) was bound by M. pneumoniae in considerable amounts from both GPS and purified C1. The C1 bound by the cells was reacting with C4. Sequential addition of C1, C4, C2, and C-ethylenediaminetetraacetate to glass-grown M. pneumoniae cells resulted in rounding of a significant number of cells. M. orale and M. fermentans showed a reduced binding capacity for C1 as compared with M. pneumoniae. Both species were only slowly killed by fresh GPS, whereas M. hominis was as sensitive as M. pneumoniae. The results suggest an antibody-independent interaction between some components of the membrane surface of M. pneumoniae and C1, resulting in an activation of the complement system leading to the killing of the mycoplasma cells.

Animals↗
PubMed1978

The presence of active C1 (C-1) on peripheral human lymphocytes.

We have shown that the first component of complement C1 is present in an active form on the surface of washed human peripheral lymphocytes but not on platelets or erythrocytes. This active C1 (C-1) was detected by its ability to transfer to sensitized cells carrying C4, i.e., EAC4, forming EAC-1,4. Active C1 was also able to consume C4. Treatment of these lymphocytes with 0.02 M EDTA removed C-1. EDTA-treated lymphocytes were able to bind exogenous purified human C-1. Comparative studies with sentized erythrocytes (EA) and EDTA treated lymphocytes showed that although fewer molecules of exogenous C1 could bind to the EDTA-treated lymphocytes than to EA, the consumption of C4 by C-1 bound to lymphocytes was significantly higher than that observed with EAC-1. When lymphocytes obtained from 2 patients with chronic lymphocytic leukemia and hypocomplementemia were tested, the release of C1, the C4 consumption and the binding of C-1 to EDTA-treated cells were highly inefficient.

Blood Platelets↗
PubMed1977

Biosynthesis of the first component of complement by human fibroblasts.

1. Haemolytic activity corresponding to that of the first component of complement (C1) was synthesized and secreted by all nine human fibroblast cell lines examined. No activity was found in the culture media of a variety of other human cell lines. 2. The component-C1 haemolytic activity secreted by the fibroblast lines behaved in an identical manner, in most respects, with that of the component-C1 haemolytic activity of human serum. The component-C1 haemolytic activity secreted by fibroblasts, however, was less susceptible to inhibition by rabbit fragment F(ab')(2) anti-(human subcomponent C1q) than was the component-C1 haemolytic activity of human serum. 3. Biosynthesis of fibroblast component-C1 haemolytic activity was inhibited by the presence of cycloheximide and regained on its removal. 4. Incorporation of radioactivity into proteins secreted by the fibroblasts and release of component-C1 haemolytic activity by the fibroblasts both increased in a linear manner until several days after the cultures had reached a state of confluent growth. 5. Radioactivity was incorporated into subcomponents C1q, C1r and C1s, as judged by the formation of specific immunoprecipitates and by absorption with immune aggregates. 6. The immunoprecipitates formed by using antisera against subcomponents C1r and C1s were run on polyacrylamide gels in sodium dodecyl sulphate, and this provided convincing physiochemical evidence for the biosynthesis of these subcomponents de novo. 7. The results obtained with immunoprecipitates formed by using anti-(subcomponent C1q) suggest that subcomponent C1q may be synthesized and secreted by fibroblast cell lines in vitro, in a form with a higher molecular weight than that of subcomponent C1q which is isolated by conventional techniques of protein fractionation from fresh serum.

Cell Line↗
PubMed1984

Lysis of horse red blood cells mediated by antibody-independent activation of the alternative pathway of chicken complement.

Horse red blood cells (HRBC) were found to be lysed when incubated with fresh normal chicken serum (NCS). By comparison of the properties of the lysis of HRBC with those of the complement-dependent lysis of sheep red blood cells (SRBC) sensitized with haemolytic antibody via the classical pathway, the following differences were observed between the two haemolytic phenomena. (i) The lysis of HRBC was independent on antibody in contrast to the antibody dependence of the lysis of sensitized SRBC. (ii) The lysis of HRBC was dependent on Mg but not on Ca ion, whereas the lysis of sensitized SRBC required both Mg and Ca ions. (iii) Treatment of NCS with carrageenan that acts as an inactivator of the first component of complement (C1) inhibited the lysis of sensitized SRBC but not the lysis of HRBC. (iv) C1 was consumed in the lysis of sensitized SRBC but not in the lysis of HRBC. (v) Cobra venom factor (CVF), C3 inactivator via the alternative complement pathway, inhibited the lysis of HRBC but not the lysis of sensitized SRBC. (vi) Minimal reaction times for the lysis of HRBC and for the lysis of sensitized SRBC were 90 and 60 min, respectively. These findings indicate that the lysis of HRBC was caused by the antibody-independent activation of complement via the alternative pathway.

Animals↗
PubMed1983

Measurement of antibody-dependent binding, proteolysis, and turnover of C1s on liposomal antigens localizes the fluidity-dependent step in C1 activation.

The antibody-dependent binding and activation of the first component of human complement (C1) by liposomes containing nitroxide spin-label lipid haptens have been simultaneously measured. The liposomes were either fluid (dimyristoylphosphatidylcholine) or solid (dipalmitoylphosphatidylcholine) at the temperature of the experiments (32 degrees C). In 10 minutes fluid liposomes activate 40% of the C1 whereas solid liposomes only activate 10% of the C1. The fraction of C1 bound at the end of the activation incubation is approx. 2% for fluid liposomes and approx. 4% for solid liposomes. This binding is consistent with the relative amounts of antibody which bind to these two types of liposomes. These results demonstrate turnover of C1 or C1r2s2 on the liposome surface. It is concluded that the differential activation of C1 is due to a difference in the rate of activation of C1 after it is bound to the liposome surface. Lower limits for the activation rate constant for C1 bound to fluid and solid liposomes are estimated to be 8 X 10(-2) s-1 and 1 X 10(-2) s-1, respectively.

Animals↗
PubMed1983

Nature of the metal ion requirement for assembly and function of the first component of human complement.

The first component of human complement (C1) was reconstituted from equimolar concentrations of its purified subunits C1q, C1r, and C1s, in the presence of each of nine different metal ions for the purpose of studying the qualitative and quantitative nature of the metal ion requirement for C1 assembly and function. For C1 reconstituted with each metal ion, three assays characteristic of C1 were performed as follows: (1) spontaneous C1 activation in the absence of the regulatory protein C1-inhibitor was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis by simultaneously quantifying the specific proteolysis of the C1r and C1s subunits; (2) C1 activation induced by aggregated IgG in the presence of C1 inhibitor was similarly analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis; and (3) formation of 16 S macromolecular C1 was determined in the analytical ultracentrifuge. For all experiments, trace metal contaminants were removed from buffers and proteins. All divalent cations tested from the first transition period of the periodic table (i.e. Ca2+, Mn2+, Co2+, Ni2+, and Zn2+) effectively mediated the formation of functional macromolecular C1. Dose curves showed maximal C1 assembly and activation at ion concentrations of 30 to 50 microM for each of the above metal ions. However, when ion concentrations were increased above 50 microM, C1 assembly and activation became inhibited. The further to the right in the periodic table, the better inhibitor was the metal ion. Competition experiments indicated that the ion binding sites mediating inhibition are distinct from those promoting activation. Other metal ions that also effectively mediated C1 assembly and function were Cd2+ and Tb3+; however, Mg2+ and Ba2+ were ineffective. All metal ions that mediated C1 assembly and activation also promoted C2 consumption by C1 in normal human serum treated with aggregated IgG. In conclusion, the assembly and function of C1 can be mediated by numerous metal ions. In direct opposition to accepted theory, there is no specific requirement for calcium.

Calcium↗
PubMed1975

Complement-mediated bactericidal system: evidence for a new pathway of complement action.

The early components of human complement (C1, C4, and C2) plus certain serum euglobulins will kill pathogenic strains of Shigella sonnei. Serum from patients with hereditary C3 deficiencies and specific antiserums to C3, C5, and C6 were utilized to demonstrate the absence of requirements for late-acting complement components in this unusual bactericidal system.

Antibodies, Bacterial↗
PubMed1987

Antibody-independent activation of the classical pathway of complement by Epstein-Barr virus.

A purified preparation of Epstein-Barr virus (EBV) has been shown to activate the classical complement pathway by direct interaction with the first component of complement, C1, without the intervention of antibody. No evidence was found for activation of the alternative pathway. Following classical pathway activation the specific affinity of EBV for B cells can be presumed to be lost since the virus will become opsonized for clearance by phagocytic cells bearing complement receptors, CR1 and CR3. This activation is further evidence that complement plays a role in defence mechanisms independently of antibody activity.

Antigens, Viral↗
PubMed1976

Cooperative binding of a complement component to antigen-antibody complexes. III. Complexes containing IgM antibodies.

The first component of guinea pig complement (C1)2) is bound in a cooperative manner to antigen-antibody complexes containing rabbit IgM antibodies, as was previously shown to be the case for IgG antibodies. The shape of the binding curves is consistent with an allosteric mechanism involving clusters of 10 interacting C1 binding sites. Similar results were obtained with IgM antibodies against an artificial hapten and against a natural constituent of the erythrocyte membrane.

Allosteric Regulation↗
PubMed1981

Studies on immunopathogenesis in epidemic hemorrhagic fever: sequential observations on activation of the first complement component in sera from patients with epidemic hemorrhagic fever.

Sequential measurements of activation of the 1st component of complement (C1) in the sera of 29 patients hospitalized with epidemic hemorrhagic fever (EHF) were performed according to a method recently developed. These patients were treated with supportive, routine therapy, but not immunosuppressive agents. This paper describes the kinetic observations on the activation of C1 in the 29 cases. The data confirm that an apparently increased extent of activation occurred in their sera. It was found that the more severely ill the patients were, the more apparent the activation. Additionally, beginning with the 15th day of disease, the extent of C1 activation diminished in most of the moderate and severe types of patients, but not in those with moribund illness and fatal ones. On the basis of the study, it may be reasonably concluded that C1 activation was correlated well with the severity and clinical course of EHF, indicating that the classical C pathway was activated in these patients. We feel that our findings are important to an understanding and elucidation of the immunopathogenetic mechanisms of EHF.

Adolescent↗
PubMed1988

Antibody-independent activation of the complement system by mitochondria is mediated by cardiolipin.

Non-immune activation of the first component of complement (C1) by the heart mitochondrial inner membrane has been investigated. Cardiolipin, the only strong activator of C1 among phospholipids, is present in large amounts in the heart mitochondrial inner membrane. We therefore studied its contribution to C1 activation by mitochondria. The proteins of the mitochondrial inner membrane were found to activate C1 only weakly, in contrast with the phospholipid fraction which induces strong C1 activation. Furthermore, the digestion of mitochondrial inner membranes with proteolytic enzymes did not affect C1 activation. Additional support in favour of cardiolipin being the responsible activator came from competition experiments with mitochondrial creatine kinase (mt-CPK) and adriamycin, known to bind to cardiolipin. Both mt-CPK and adriamycin displaced C1q from the mitochondrial inner membrane. In addition, C1q displaced mt-CPK bound to mitoplasts.

Animals↗
PubMed1980

Kinetic measurement of the interaction of rheumatoid factor with IgG-coated latex particles and the influence of the first component of human complement.

Interaction between isolated rheumatoid factor (RF) of the IgM class or sera from patients with rheumatoid arthritis (RA) and IgG-coated latex particles has been studied kinetically by means of standard aggregometer equipment. The agglutination of particles mediated by isolated RF or RA-sera is inhibited by fresh normal human serum (NHS). The RF-inhibiting principle is heat-labile and recovered in the high molecular weight fractions of NHS separated on a G-200 column. Partially purified first component of complement, C1, also inhibits RF-mediated particle agglutination and disintegrates preformed RF-IgG-latex particle agglutinates. Addition of C1 to heated (56 degrees C, 30 min) NHS restores its RF-inhibiting activity. The most probable basis of this serum activity is competition between C1 with higher affinity for IgG bound to particles and RF. After about 5 min of incubation of NHS with IgG-latex particles the RF-inhibiting activity is gradually lost and interpreted to mean that C1 during the activation of the complement system is discharged from IgG bound to particles. The RF-inhibiting activity of NHS gradually decreases by incubation of serum with increasing doses of activators of the classical complement pathway probably due to the inability of activated C1 to hinder RF-interaction with IgG-particles. The presence in certain RA-sera of C1 in mainly activated form explains why such sera, even if they are fresh are able to agglutinate IgG-particles.

Complement Activation↗
PubMed1984

Characterization of C1q by monoclonal antibodies.

The effect of a purified monoclonal anti-C1q antibody (Ab 242 G3) on the function of C1q, a subcomponent of the first component of complement C1, was studied. No inhibition of purified activated C1 was observed, whereas binding of the Ab to fluid phase C1q, to C1q bound to immune complexes (EAC1q), or to serum C1 in fluid phase resulted in a dose-dependent inhibition of the hemolytic activity of C1. In contrast, when the effect of the Ab on serum C1 bound to immune complexes (EAC1) was measured, no inhibition but a dose-dependent enhancement of the hemolytic activity was obtained. The dose-response curve of the Ab-treated cell bound serum C1 was indistinguishable from that of activated C1. Isolated Fab fragments of this Ab did not cause an increase in C1 activity. After separation of the A, B, and C chains of C1q by SDS-PAGE, Ab 242 G3 reacted in immunoblotting selectively within the C chain. These data indicate that cross-linking of C1q via the C chain of C1q might lead to an internal activation of C1. One out of seven monoclonal antibodies generated against mouse macrophages (M phi was found) to recognize isolated heterologous C1q. This antibody was shown to be cytotoxic and to react in a strain independent way with mouse M phi derived from bone marrow cells as well as with M phi from the peritoneal activity. However, it did not react with mouse granulocytes, thymocytes, T- and B-lymphocytes. The hemolytic activity of fluid phase C1q was inhibited to 50% at a 2 X 10(-4) dilution of hybridoma supernatant, whereas a 100-fold higher concentration was required to inhibit C1q bound to immune complexes (EAC1q) to the same extent. It was demonstrated that this antibody recognizes the isolated globular, Fc-binding portions of the C1q molecule and react with the A and B chains. Since M phi have been shown to synthesize C1q, the Fc-recognizing subcomponent of the first component of complement, evidence was provided that endogenous C1q can serve as an Fc receptor on M phi during secretion. This was demonstrated by a dose-dependent inhibition of Fc receptor activity for EIgG by the F (ab')2 fragment of this monoclonal antibody. In a fluorescence activated cell sorter (FACS) analysis Ab 146 F (ab')2 recognizes up to 75% of unstimulated NMRI peritoneal exudate cells (PEC), 60% and 53% of cells stimulated by thioglycollate and ConA, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1977

Further studies on the identification of the subcomponents of the first component of complement after affinity chromatography of human serum on IgG-sepharose.

Affinity chromatography of serum on IgG covalently linked to Sepharose results in the retention of the proteins of the first component of complement (C1). A fraction called pool II is eluted from this column with 0.025 M EDTA and has previously been shown to contain C1s and a novel protein believed to be part of the C1 complex and called C1t. C1r has now been located in pool II and these three proteins were purified by DEAE cellulose chromatography. C1r and C1s were recovered in the proenzyme form and their identity was established by SDS polyacrylamide gel electrophoresis before and after reduction and alkylation, and on the basis of their esterolytic activities toward different substrates. The properties of C1r from pool II are contrasted with those of the protein recovered from the pool III eluate of the affinity column and previously thought to be C1r.

Chromatography, Affinity↗
PubMed1988

Macromolecular organization of natural and recombinant lung surfactant protein SP 28-36. Structural homology with the complement factor C1q.

The macromolecular structure of the pulmonary surfactant apolipoprotein SP 28-36 has been determined. For SP 28-36 isolated from dog lung lavage, a flower bouquet-like hexameric structure with six globular domains connected by short stalks to a common stem was revealed by electron microscopy, using the rotary shadowing technique. This structure is very similar to that published for the subcomponent C1q of the first component of complement C1. The lavage material was compared with the homologous human recombinant SP 28-36 by the same technique. Mostly smaller aggregates like di-, tri- and tetramers as well as very high aggregates were observed. Mild reduction of the recombinant material revealed the lollipop-shaped monomers composed of a globular domain and a tail with a discrete kink in the middle portion. The collagenous nature of the tail was demonstrated by circular dichroism spectroscopy. This implies that the mammalian expression system assembles the monomeric subunits correctly. Assembly into the hexameric structures, however, does not proceed quantitatively.

Animals↗